volume 27, issue 1, P229-241 2013
DOI: 10.1016/j.idc.2012.11.011
View full text
Daniel M. Musher

Abstract: Vaccination with a preparation that currently contains 23 pneumococcal capsular polysaccharides (PPV23) successfully reduces the risk of serious pneumococcal infection by an estimated 50% to 80%. Because infants and young children do not respond to polysaccharide antigens, a conjugated polysaccharide vaccine that first contained 7 capsule types (PCV7) and now contains 13 capsule types (PCV13) was developed for use in them. A single study in patients with AIDS showed protection against pneumococcal disease by P…

expand abstract